Identification of four immune subtypes in locally advanced rectal cancer treated with neoadjuvant chemotherapy for predicting the efficacy of subsequent immune checkpoint blockade.

Among the samples that could be classified after treatment, the PCR rates of C1, C2, and C3 subtypes were 50.0% (1/2), 83.3% (5/6), and 25.0% (1/4), respectively, which did not reach statistical significance (Fisher’s exact probability, P = 0.192).

also in 111,027 other papers